Performance evaluation of new fluorescent-based lateral flow immunoassay for

quantification of HbA1c in diabetic patients

Nadin Younes^{1,2}, Mahmoud M. Al Ghwairi³, Amin F. Majdalawieh⁴, Nader Al-Dweik^{5,6,7,8,9},

Gheyath K. Nasrallah^{1,2,*}

¹ Biomedical Research Center, Qatar University, Doha 2713, Qatar.

² Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha 2713, Qatar.

³ Sciences of medical laboratory, Laboratory Analysis technologists, Al-Ahliyya Amman University, Amman 2213, Jordan.

⁴ Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, a, Sharjah 26666, United Arab Emirates.

⁵ Department of Pediatrics and Neonatology, Neonatal Intensive Care Unit, Newborn Screening Unit, Women's Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar

⁶ Genomics and Precision Medicine (GPM), College of Health & Life Science (CHLS), Hamad Bin Khalifa

University (HBKU), Doha 34110, Qatar

⁷ Department of Research, Women's Wellness and Research Center, Hamad Medical Corporation, Doha 3050, Qatar

⁸ Interim Translational Research Institute (iTRI), Hamad Medical Corporation (HMC), Doha 3050, Qatar

⁹ School of Life Science, Pharmacy and Chemistry, Faculty of Science, Engineering & Computing, Kingston University, Kingston University London, River House, 53–57 High Street, Kingston upon Thames, London KT1 1LQ, UK

* Correspond to: Gheyath K. Nasrallah

Department of Biomedical Science, College of Health Sciences, Qatar University, Doha, Qatar

Women's Science building, C01, Tel: +974 4403 4817, Fax: +974-4403-1351, P.O. Box 2713, email:

gheyath.nasrallah@qu.edu.qa.

Abstract

Background: Rapid and constant HbA1c level monitoring is essential in slowing the progression of Type 2 diabetes. This need becomes challenging in low resources countries where the social burden of the disease is overwhelming. Recently, fluorescent-based lateral flow immunoassays (LFIAs) gained wide attention for small or non-laboratory settings and population surveillance. Aim: This study aim to evaluate the performance of novel fluorescence-based LFIA FinecareTM HbA1c Rapid Quantitative Test for quantitative measurement of HbA1c along with its reader (Model No. FS-113). Methods: We conducted a retrospective study using 147 samples (fingerstick and venepuncture whole blood samples) analysed by FinecareTM HbA1c Rapid Quantitative Test. For validating FinecareTM measurements, results were compared with results of the reference assay: Roche Cobas Pro c 503. **Results:** FinecareTM showed 92.7% sensitivity and 94.7% specificity compared to the Roche Cobas Pro c 503 using fingerstick whole blood samples. On the other hand, FinecareTM showed 98.7% sensitivity and 100% specificity compared to the Roche Cobas Pro c 503 using venepuncture blood samples. Cohen's Kappa statistic denoted excellent agreement with Roche Cobas Pro c 503, with values being 0.84 (95% CI: 0.72-0.97) and 0.97 (95% CI: 0.92-1.00) using fingerstick whole blood samples and venous blood, respectively. In addition, a strong correlation was observed between FinecareTM/Roche Cobas Pro c 503 (r>0.9, p<0.0001) with fingerstick and venous blood samples. Most importantly, FinecareTM showed a significant difference between the normal, pre-diabetic, and diabetic samples (p<0.001). Conclusion: FinecareTM is a reliable assay and can be easily implemented for long-term monitoring of HbA1c in diabetic patients, particularly in none or small laboratory settings.

1. Introduction

Glycated haemoglobin (HbA1c) serves as a reliable indicator of glycemic status in diabetic patients over a period of two to three months (1). HbA1c is produced once haemoglobin is chemically linked to glucose (1). Traditionally, high plasma glucose levels were used for diagnosis of diabetes mellitus. This could be done after fasting, two hours after an oral glucose (75 g) tolerance test, or after a random blood glucose check in symptomatic patients (2). Recently, the American Diabetes Association and the World Health Organisation (WHO) recommended the use of HbA1c ($\geq 6.5\%$) for the diagnosis of diabetes mellitus (3). This was based on the fact that HbA1c's can predict clinical outcomes of the disease. In this context, many studies showed that HbA1c has a strong correlation with the chronic microvascular complications of diabetes, including retinopathy, nephropathy and neuropathy (4, 5).

Despite the fact that HbA1c testing is currently more expensive than blood glucose testing (the average net cost of a HbA1c test is 13.6 times that of a plasma glucose measurement), it offers substantial practical benefits (6). Most importantly, HbA1c testing can be conducted at any time throughout the day and does not require any special pre-test preparation by the patient (such as overnight fasting) (6, 7). Therefore, rapid and constant monitoring HbA1c helps in slowing the progression of type-2 diabetes in patients. However, this need becomes a challenge in limited-resource settings lacking laboratory infrastructure, where the social burden of the disease is often overpowering (8). The current laboratory diagnostic techniques for HbA1c such as cation-exchange HPLC, affinity chromatography, and capillary electrophoresis, involve expensive instruments, laborious and require a long turnaround time (9). Under these conditions, constant testing and monitoring can be facilitated by point-of-care (POC) devices. However, existing POC devices for HbA1c often require trained personnel and large equipment and are therefore not suited for non-laboratory testing.

Lateral flow immunoassays (LFIAs) are attractive for small or point of care settings and population surveillance. They are rapid, in expensive, simple to use, most importantly, rely on easily accessible samples such as whole blood from fingerstick. The FinecareTM HbA1c Rapid Quantitative Test is a fluorescence immunoassay used along with FinecareTM FIA System for quantitative determination of HbA1c in human blood (venepuncture or fingerstick). In this study, we aimed to evaluate the performance of FinecareTM HbA1c Rapid Quantitative Test by using samples obtained by fingerstick and venepuncture. In addition, to compare the performance of FinecareTM HbA1c Rapid Quantitative Test with the reference technique; Roche Cobas pro c 503 clinical chemistry analyzer from Roche Diagnostics.

2. Methods

2.1 Sample collection and ethical approval

This is a retrospective study. Thus, no patients/applicants were recruited and there was no direct or indirect interaction with any human subject. The study was conducted on existing de-identified testing results obtained from the manufacturer to conduct the analysis. Fingerstick and matched venous blood sample was drawn from a total of 147 participants in two different laboratories (one private lab and another lab that belongs to the ministry of public health in Jordan). Ethical approval exemption has been granted (QU-IRB 1766-E/22) from Qatar University.

2.2 Finecare[™] HbA1c rapid quantitative test

The FinecareTM HbA1c Rapid Quantitative Test is based on fluorescence immunoassay technology. The test uses a sandwich immunodetection method to measure percentage of HbA1c in human blood. Briefly, 20 μ L of fingerstick or venepuncture blood was added into detection buffer tube. After that, 75 μ L of sample mixture was loaded into the

sample well and was inserted into the test cartridge holder of FinecareTM FIA meters. The reaction time is 5 minutes.

2.3 Reference method Roche Cobas Pro c 503

The Tina-quant Hemoglobin A1cDx assay is intended to diagnose diabetic patients. It is in vitro diagnostics assay to quantify hemoglobin A1c (mmol/mol) and % hemoglobin A1c in hemolysate or venous whole blood on the cobas c 503 clinical chemistry analyzers. This approach is based on the turbidimetric inhibition immunoassay of blood samples that have been hemolyzed. The anti-HbA1c antibody forms a soluble complex with a single binding site on HbA1c. Polyhaptens react with excess anti-HbA1c antibody to generate an insoluble compound, which is evaluated by turbidimetry.

2.5 Statistical method

Correlation and linear regression analysis were conducted between FinecareTM and the reference method; Roche Cobas Pro c 503. Because our data was not normally distributed, spearman correlation coefficient (r) was calculated. For absolute values of spearman's r, 0–0.19 is denoted as very weak, 0.2–0.39 as weak, 0.40–0.59 as moderate, 0.6–0.79 as strong, and 0.8–1 as very strong correlation (10).

Concordance analysis between FinecareTM and the reference methods Roche Cobas Pro c 503 was conducted, which includes the overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA), accuracy/efficiency as well as Cohen's Kappa statistic, which is a robust metric that estimates the level of agreement between two diagnostic tests. A Cohen's Kappa coefficient <0.40 suggests a poor agreement, 0.40–0.59 suggests a fair agreement, 0.60–0.74 suggests a good agreement, and \geq 0.75 suggests an excellent agreement (11). Finally, we assessed the area under (a ROC) curve, which measures the accuracy of a quantitative diagnostic test (12). An AUC of 0.9–1.0 is denoted as excellent, 0.8–0.9 is denotes as very good, 0.7–0.8 is denoted as good, 0.6–0.7 is

denoted as sufficient, 0.5–0.6 is denoted as bad, and <0.5 is denoted as not useful. The significance level was indicated at 5%, and a 95% confidence interval (CI) was reported for each metric. All statistical analysis was performed using GraphPad Prism software (Version 9, San Diego, CA, USA).

3. Results

3.1. FinecareTM results are comparable to the standard laboratory method

Roche Cobas Pro c 503

We assessed the performance of FinecareTM using fingerstick and venepuncture whole blood samples in comparison to Roche Cobas Pro c 503.

The overall distribution of the values generated by each automated analyzer against the cutoffs (dashed lines) is shown in **Figure 1**. As depicted in **Figure 1**, there was no significant difference between results obtained from FinecareTM and Roche Cobas Pro c 503 analytical analyser using the fingerstick or venous blood samples.




Figure 1. Distribution of numerical results obtained from fingerstick whole blood and venous blood using FinecareTM machine and the reference method; Roche Cobas Pro c 503. Nonparametric Kruskal-Wallis test was used to compare the differences between groups.

3.2. FinecareTM showed low level of false positive and false negative comparable to that of the standard laboratory method

According to the current recommendations, patients with a HbA1c level $\geq 6.5\%$ would get intensive treatment. To assess the clinical application of FinecareTM, the HbA1c results were compared with those of the conventional laboratory results using a cut-off point of 6.5% for HbA1c using fingerstick and venous blood samples, as shown in Table 1 and Table 2. Using fingerstick whole blood, 4 samples showed false positive results (4%) and two samples (2%) showed false negative results using FinecareTM as shown in Table 1. Whereas, using venous blood samples, only one sample showed false positive result (1%) and none of the samples showed false negative results (0%) using FinecareTM as shown in Table 2. Similarly, as shown in Table 3, only 3 fingerstick whole blood samples showed false positive results (3%) when compared to venous blood, whereas only 2 fingerstick whole blood samples.

Cut-off: 6.5%		Reference Method Roche Cobas Pro c 503				
		POSITIVE	NEGATIVE	TOTAL		
Finecare TM	POSITIVE	23	4	27		
(fingerstick)	NEGATIVE	2	71	73		
(Ingerstick)	TOTAL	25	75	100		

Table 1. Comparison between Roche Cobas Pro c 503 and FinecareTM (fingerstick) tests.

Table 2. Comparison between Roche Cobas Pro c 503 and FinecareTM (venepuncture) tests.

Cut-off: 6.5%		Reference Method Roche Cobas Pro c 503			
		POSITIVE	NEGATIVE	TOTAL	
Finecare TM	POSITIVE	25	1	26	
(venepuncture)	NEGATIVE	0	74	74	
	TOTAL	25	75	100	

Table 3. Comparison between FinecareTM (venepuncture) and FinecareTM (fingerstick) tests.

Cut-off: 6.5%		Finecare TM (venepuncture)			
		POSITIVE	NEGATIVE	TOTAL	
Finecare TM	POSITIVE	24	3	27	

(fingerstick)	NEGATIVE	2	71	73
	TOTAL	26	74	100

3.3. FinecareTM demonstrates high sensitivity and specificity comparable to that of the standard laboratory method

As shown in Table 4, FinecareTM demonstrated 100% sensitivity and 98.7% specificity compared to the standard laboratory method using venous blood samples. Whereas FinecareTM showed lower sensitivity (92.0%) and specificity (94.7%) compared to the reference method using fingerstick whole blood. In addition, we evaluated the sensitivity and specificity of FinecareTM using fingerstick in comparison to venous blood samples. As expected, using fingerstick whole blood showed lower sensitivity (92.3%) and specificity (95.9%) compared to venous blood.

The concordance assessment between the reference method Roche Cobas Pro c 503 and FinecareTM using venous and fingerstick whole blood samples is reported in Table 4. The tests' agreements were studied in a pairwise fashion applying inter-rater agreement statistics; (Cohen's Kappa coefficient, κ). The OPA, PPV, and NPV between Roche Cobas Pro c 503 and FinecareTM using venous blood were 99%, 98.67%, and 100%, respectively, whereas using fingerstick whole blood were 94%, 94.67%, and 92%, respectively. Most importantly, Cohen's Kappa coefficient denoted excellent agreement between FinecareTM and Roche Cobas Pro c 503 ($\kappa > 0.75$) using fingerstick and venous whole blood samples.

503.								
Reference	Test	Overall Percent Agreeme nt (OPA)	Sensitivi ty	Specifici ty	Positive Predicti ve Value (PPV)	Negativ e Predicti ve Value (NPV)	Accura cy/ Efficien cy	Cohen's Kappa Coefficie nt
Roche	Finecare TM	94%	92.0%	94.7%	85.2%	97.3%	94%	0.84

(86.9 -

98.5)

98.7%

(92.8-

(66.3-

95.8)

96.2%

(78.1 -

(90.5-

99.7)

100%

(95.1-

(87.4-

97.8)

99%

(94.6-

(0.72 -

0.97)

0.97 (0.92-

(74.0 -

100% (

86.3-

99)

Cobas Pro

Cobas Pro

c 503

Roche

(fingerstick

FinecareTM

(venepunct

(87.4-

97.8)

99%

(94.6-

Table 4. Concordance assessment between $Finecare^{TM}$ fingerstick, venepuncture test and Roche Cobas Pro c 503.

c 503	ure)	100)	100)	100)	99.4)	100)	100)	1.00)
Finecare TM	Finecare TM	95%	92.3%	95.9%	88.9%	97.3%	95%	0.87
(venepunct	(fingerstick	(88.7-	(74.9-	(88.6-	(70.8-	(90.5-	(88.7-	(0.76-
ure))	98.4)	99.1)	99.2)	97.6)	99.7)	98.4)	0.98)

3.4. Very strong correlation between $\mathbf{Finecare}^{\mathrm{TM}}$ and the standard laboratory method

Roche Cobas Pro c 503.

We assessed the correlation between FinecareTM with the standard laboratory method; Roche Cobas Pro c 503 using fingerstick and venous blood samples as shown in **Figure 2**. A very strong correlation was observed (r=0.95, p<0.0001) between FinecareTM using fingerstick whole blood sample and Roche Cobas Pro c 503. Similarly, very strong correlation was observed (r=0.97, p<0.0001) between FinecareTM using venous whole blood sample and Roche Cobas Pro c 503. Similarly very strong correlation was observed (r=0.97, p<0.0001) between FinecareTM using venous whole blood sample and Roche Cobas Pro c 503. The linear regression analysis showed that constructed model could strongly predict the dependent variable (R²=0.9, p<0.0001) between FinecareTM using venous or fingerstick samples.

Receiver-Operating Characteristic (ROC) curve analyses showed excellent performance for FinecareTM with an Area Under the Curve (AUC) of 0.994 and 0.998 using fingerstick and venous blood samples, respectively (**Figure 3**).




Figure 2. Pairwise correlation analysis and linear regression analysis of the numerical values obtained by each assay. Spearman correlation coefficient (r), and p value are indicated. Coefficient of determination (R^2) was calculated to be 0.952, 0.969, 0.937 for fig A, B, and C, respectively.




Figure 3. ROC curve for FinecareTM. An AUC of 0.9–1.0 is considered excellent. AUC, area under the curve; ROC, Receiver Operating Characteristic.

3.5 FinecareTM test could distinguish between the pre-diabetic and diabetic groups

similar to the standard laboratory method.

We classified the participants into three groups according to ADA (American Diabetes Association): <5.7% (no diabetes), 5.7-6.5% (pre-diabetes), \geq 6.5% (diabetes). Similar to the reference method, FinecareTM showed a significant difference between the normal, pre-diabetic, and diabetic samples (*p*<0.001) as shown in **Figure 4**.




Figure 4. Distribution of numerical results obtained from fingerstick whole blood and venous blood using FinecareTM machine and the reference method; Roche Cobas Pro c 503. Results are represented as dot plots. Data are presented for 100 patients (normal <5.7%, pre-diabetic 5.7-6.4%, diabetic \geq 6.5%) from each assay. Nonparametric Kruskal-Wallis test was used to compare the differences between groups.

3.6 FinecareTM showed excellent performance and reproducibility in another laboratory.

To ensure the reproducibility of the results, the performance of FinecareTM was evaluated in another laboratory. FinecareTM showed 80% sensitivity and 100% specificity compared to the reference method (**Table 5**). Nevertheless, similar to our results, a very strong correlation was observed (r=0.97, p<0.0001) between FinecareTM and Roche Cobas Pro c 503 as shown in **Figure 5**.

Cut-off: 6.5%		REFERENCE METHOD Roche HbA1c			
		POSITIVE	NEGATIVE	TOTAL	
T. TM	POSITIVE	20	0	20	
Finecare TM	NEGATIVE	5	22	27	
	TOTAL		22	47	

Table 5. Comparison between FinecareTM (venepuncture) and FinecareTM (fingerstick) tests.




Figure 5. Pairwise correlation analysis and linear regression analysis of FinecareTM in comparison to Roche Cobas Pro c 503. Spearman correlation coefficient (r), and p value are indicated. Coefficient of determination (\mathbb{R}^2) was calculated to be 0.9496.

4. Discussion

This study validated the performance of Finecare[™] HbA1c Rapid Quantitative Test used along with Finecare[™] FIA System for quantitative determination of HbA1c in human blood. Our study is novel because there is no similar previous evaluation studies were found in the literature. The test is used as an aid to monitor long-term glycemic status in patients with diabetes mellitus. A total of 147 samples collected from two different labs (one private lab and another lab that belongs to the ministry of public health in Jordan) were used to evaluate the assays' performance. To our knowledge, this is the first study conducted to validate the fluorescence-LFIA-based Finecare HbA1c test, which marks the novelty of this research work.

In this study, we demonstrated that FinecareTM results are comparable to the standard laboratory method Roche Cobas Pro c 503. No significant difference between FinecareTM and Roche Cobas Pro c 503 analytical analyser using the fingerstick or venous blood samples. The correlation and linear regression analyses between the readings obtained from FinecareTM (fingerstick and venous blood samples) and the reference method; Roche Cobas

Pro c 503 was evaluated. Spearman correlation coefficients (r) demonstrated a statistically significant strong positive correlation between FinecareTM and Roche Cobas Pro c 503 with either fingerstick or venous blood samples (r>0.9, p<0.001). In addition, Cohen's Kappa statistic denoted excellent agreement between FinecareTM and Roche Cobas Pro c 503. The excellent concordance between the POC FinecareTM and Roche Cobas Pro c 503 makes it an attractive alternative for the standard laboratory technique in non-laboratory setting.

One of the key advantages of FinecareTM is obtaining quantitative results within 5 minutes using fingerstick blood samples. Even though anti \Box HbA1c antibody are more stable and persistent in plasma samples, the fingerstick whole blood samples are more convenient and easier to use. Thus, we evaluated the efficacy of FinecareTM utilizing whole blood samples obtained through fingerstick to blood samples obtained via venipuncture. Using FinecareTM, a very good correlation (*r*=0.905, *p*<0.0001) was detected between fingerstick and venous plasma samples. Our results validated the feasibility of utilizing whole blood sample from fingerstick for HbA1c detection and showed excellent concordance with venous blood samples values using FinecareTM test. Collection of fingerstick whole blood samples in Microtainer tubes is quick and easy. It eliminates the need for a phlebotomist, making it an attractive alternative for use in POC settings. The simplicity of performing LFIA with whole blood also eliminates the need for centrifugation and plasma separation steps, which reduce the cost and complexity of getting a quantitative result. The ability to rapidly, accurately, and affordably monitor HbA1c in diabetic patients is an important tool that will help in slowing the progression of type-2 diabetes particularly in patients residing in resource-limited areas.

In the present study, we were able to show that FinecareTM assay could be used efficiently for the long-term monitoring of HbA1c in diabetic patients. To ensure the reproducibility of the results, the performance of FinecareTM was evaluated in another laboratory. The assay performs with high reproducibility (80%) with the two runs repeats

done on two different samples taken from two different laboratories. In addition, FinecareTM showed reproducible very high specificity (100%) compared to the reference method. Furthermore, a very strong correlation was also observed (r=0.97, p<0.0001) between FinecareTM and Roche Cobas Pro c 503. In conclusion, FinecareTM is a reliable assay and can be easily implemented for long-term monitoring of HbA1c in diabetic patients, particularly in none or small laboratory settings.

Author Contribution

Data analysis: GKN and NY. First draft writing: GKN and NY. Review and editing: M.M.G,

A.M, and N.A.D

5. Reference

1. Zhang Q, Monroe ME, Schepmoes AA, Clauss TR, Gritsenko MA, Meng D, et al. Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res. 2011;10(7):3076-88.

2. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1(Suppl 1):S62-9.

3. Committee TIE. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34.

4. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34(1):145-50.

5. Bower JK, Brancati FL, Selvin E. No ethnic differences in the association of glycated hemoglobin with retinopathy: the national health and nutrition examination survey 2005-2008. Diabetes Care. 2013;36(3):569-73.

6. Gomez-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes P, Cuevas-Ramos D, Lerman Garber I, Rull JA. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res. 2010;41(4):302-8.

7. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? Bmj. 2009;339:b4432.

8. Nakanga WP, Crampin A, Nyirenda M. Should haemoglobin A1C be used for diagnosis of diabetes mellitus in Malawi? Malawi Med J. 2016;28(1):28-30.

9. Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3(3):446-51.

10. Miot HA. Correlation analysis in clinical and experimental studies. J Vasc Bras. 2018;17(4):275-9.

11. Kirch W. Kappa coefficient. In Encyclopedia of Public Health. Springer: Dordrecht, The Netherlands. 2008:821–2.

12. Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25-36.